Avidity Biosciences Inc. said Tuesday it’s expanding its cardiovascular collaboration with Bristol Myers Squibb Co. in a deal that will see Avidity receive $100 million upfront with the potential to earn up to $2.2 billion in milestone payments.
The news sent Avidity’s stock RNA up 30.5% in premarket trade.
Avidity will receive a $60 million…
Master your money.
Subscribe to MarketWatch.
Get this article and all of MarketWatch.
Access from any device. Anywhere. Anytime.
Already a subscriber?
Log In
